ABBV

AbbVie Inc.

172.69 USD
+2.30 (+1.35%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AbbVie Inc. stock is up 9.95% since 30 days ago. The dividend yield is 3.60% and its next earnings date is Jul 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 11 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
21 Jun 17:06 19 Jul, 2024 165.00 CALL 81 1864
21 Jun 17:23 21 Jun, 2024 165.00 CALL 60 5349
21 Jun 18:07 19 Jul, 2024 175.00 PUT 60 39
21 Jun 19:04 19 Dec, 2025 120.00 CALL 6 42
24 Jun 13:49 20 Sep, 2024 155.00 CALL 20 248
24 Jun 14:15 17 Jan, 2025 160.00 PUT 50 3430
24 Jun 14:49 19 Jul, 2024 170.00 CALL 150 3821
24 Jun 14:58 20 Sep, 2024 165.00 CALL 60 1525
24 Jun 15:48 20 Sep, 2024 170.00 CALL 79 1988
24 Jun 16:05 20 Sep, 2024 185.00 CALL 176 1727

About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

  • Cantor Fitzgerald
    Thu Jun 20, 12:47
    buy
    confirm
  • Piper Sandler
    Tue Jun 18, 08:31
    buy
    confirm
  • HSBC
    Wed Jun 5, 06:06
    buy
    upgrade